0.1% uracil cream
Palmar-Plantar Erythrodysesthesia
Nanometics (d.b.a. PHD Biosciences)Phase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Palmar-Plantar Erythrodysesthesia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inno-206 Swiss Cancer Institute | Phase 3 | BB |
Mecobalamin Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 | B |
Dfn-15 Affiliated Hospital of Qinghai University | Phase 3 | B |
Tazarotene Dana-Farber Cancer Institute | Phase 2 | CCC |
INDOMETACINUM National Taiwan University Hospital | Phase 2 | CCC |
View all 11 →
Same molecule, other indications
0.1% uracil cream is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →